Context Therapeutics Inc (CNTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.61M
Last updated: Nov 17, 2026 at 11:04 AM ET
Context Therapeutics Inc (CNTX) Stock Forecast
Analysts expect Context Therapeutics (CNTX) to earn -$0.41 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 6 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 30.0% |
| Buy | 6 | 60.0% |
| Hold | 1 | 10.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.41
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.42
- EPS consensus
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.42 to -$0.39 | 4 |
| Dec 31, 2027 | -$0.42 | -$0.59 to -$0.31 | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.11 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.11 | -$0.17 to -$0.07 | 11 |
| Mar 31, 2027 | -$0.10 | -$0.11 to -$0.08 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 9 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 6 |
| Fiscal year ending Dec 31, 2027 | 4 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.45.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.41 | -$0.46 | -$0.46 | -$0.46 | -$0.45 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.42 | -$0.44 | -$0.44 | -$0.44 | -$0.41 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.10 | -$0.10 | -$0.10 | -$0.10 | N/A |
Frequently Asked Questions About CNTX
What is the CNTX stock forecast?
Consensus analyst estimates put Context Therapeutics's EPS at -$0.41 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate CNTX stock?
Of 10 analysts covering Context Therapeutics, 3 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CNTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.41, with estimates from -$0.42 to -$0.39 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.42, with estimates from -$0.59 to -$0.31 from 7 analysts.
How many analysts cover CNTX?
10 analysts rate Context Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CNTX pages: Overview, Earnings, Forecast, Financials, Competitors